STOCKHOLM, Sweden, Oct. 29, 2002 (PRIMEZONE) -- CMA Microdialysis AB today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the CMA Cerebral Tissue Monitoring System. The system measures intra cranial glucose, lactate, and pyruvate levels as an adjunct monitor to indicate the perfusion status of brain tissue. This is a milestone in the history of the company as it opens one of the largest markets in the world.
As to the rest, we refer to enclosed press release from CMA Microdialysis AB.
Press Release: http://reports.huginonline.com/879162/109512.pdf